A. SCC e Incorrect. SCC is a progressive ulcerating keratinocytic neoplasm that does not involve atypical mononuclear cells staining positive for CD30 and CD15. B. PG e Incorrect. PG commonly presents as a primary ulcer rather than an ulcerating nodule; the insidious course and failure to respond to A. The lesion is most likely a primary cutaneous lesion.
B. The most commonly affected site for this disease is the upper extremity.
C. The patient has a poor prognosis.
D. The cutaneous presentation of this disease is common.
E. Metastatic calcifications are a common histologic finding in this disease.
Answers:
A. The lesion is most likely a primary cutaneous lesion e Incorrect. This patient likely has secondary cutaneous HL consistent with the presence of lymphadenopathy and B symptoms. 2, 3 B. The most commonly affected site for this disease is the upper extremity e Incorrect. The most common reported site of involvement for cutaneous HL is the trunk followed by the scalp. 2 C. The patient has a poor prognosis e Correct. Case studies have found a poor prognosis associated with retrograde lymphatic and hematogenous spread to skin seen in secondary cutaneous HL. Cases of primary cutaneous HL are characterized by a more benign course and improved survival. 2, 4 D. The cutaneous presentation of this disease is common e Incorrect. Cutaneous HL is very uncommon with a prevalence of 0.5% to 3.4% among patients with HL. 3, 5 Common cutaneous symptoms and findings in patients with HL include pruritus, ichthyosis, xeroderma, urticaria, hyperpigmentation, and eczematous and psoriasiform eruptions. A. Excision e Incorrect. The treatment for secondary cutaneous HL involves chemotherapy such as the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) to treat this systemic disease.
B.
Oral corticosteroids e Incorrect. The use of oral and topical corticosteroids is inappropriate for treatment of cutaneous HL.
C.
Intralesional methotrexate e Incorrect. The use of intralesional methotrexate for a patient with signs of secondary cutaneous HL is inadequate to treat this systemic disease.
D.
Referral to hematology/oncology e Correct. The patient's biopsy results suggest classical cutaneous HL. Given there is clinical evidence of lymph node involvement with a clinical history of B symptoms, the patient is likely to have secondary cutaneous HL and requires referral to hematology/oncology for further evaluation for staging and to begin chemotherapy. After referral to hematology/oncology, the patient underwent a 6-month course of systemic chemotherapy and 1-month radiation treatment and is awaiting restaging results.
E. Skin tissue cultures e Incorrect. Cultures are appropriate in the initial evaluation when the diagnosis is unknown; however, the skin biopsy has provided a diagnosis of HL; thus, subsequent tissue cultures would not be the next best step in management.
